If you're choosing between semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound), hair loss risk is a reasonable factor to consider alongside efficacy, cost, and availability. Both drug classes have been associated with hair shedding — but the data tells a nuanced story.
This comparison reviews every available dataset to help you understand the relative risk and what drives the differences.
Clinical Trial Hair Loss Rates: Head to Head
| Metric | Semaglutide (Wegovy) | Tirzepatide (Zepbound) |
|---|---|---|
| Trial alopecia rate | ~3% | 4.9–5.7% |
| Placebo rate | ~1% | ~1% |
| FAERS ROR | 2.46 (95% CI: 2.14–2.83) | 1.73 (95% CI: 1.42–2.09) |
| Average weight loss | ~15% at 68 weeks | ~20–22% at 72 weeks |
| Mechanism | GLP-1 agonist | GLP-1 + GIP dual agonist |
| >20% weight loss alopecia rate | 5.3% | Higher (dose-dependent) |
The apparent paradox: tirzepatide shows higher alopecia rates in clinical trials (4.9–5.7% vs ~3%), yet semaglutide has a higher FAERS reporting odds ratio (2.46 vs 1.73). This likely reflects two factors. First, semaglutide has been on the market longer and prescribed more widely, generating more adverse event reports. Second, and more importantly, tirzepatide produces more aggressive weight loss — averaging 20–22% vs 15% for semaglutide — which means more metabolic stress and more telogen effluvium.
The key insight: it's the weight loss, not the molecule
When you control for the amount of weight lost, the per-unit hair loss risk is similar between the two drugs. Tirzepatide users lose more hair because they lose more weight, not because tirzepatide is inherently more harmful to hair follicles. The dose-response data from the STEP trials confirms this: semaglutide users who lost >20% body weight had hair loss rates (5.3%) comparable to tirzepatide's overall rates.
The Gender Gap
One of the most striking findings in the literature is the gender disparity. Women appear significantly more susceptible to GLP-1-related hair loss than men:
- Clinical data has shown alopecia rates as high as 7.1% in women on Zepbound compared to 0.5% in men
- A 2025 medRxiv preprint found an adjusted hazard ratio of 2.08 for hair loss in women on semaglutide (95% CI: 1.17–3.72)
- The highest-use demographic — women ages 50–64, where 1 in 5 have used a GLP-1 — also has the highest baseline risk of hair thinning
Multiple factors likely contribute: women have higher rates of baseline iron deficiency, greater sensitivity to hormonal fluctuations from weight loss, and different adipose tissue distribution patterns that may accelerate metabolic stress during rapid fat loss.
For women experiencing hair loss on GLP-1s, our women's hair loss treatment guide covers spironolactone, oral minoxidil dosing for women, and gender-specific nutritional targets.
The Paradoxical Benefit: When GLP-1s Help Hair
Not all the news is bad. Three published case studies documented significant hair regrowth in patients with inflammatory scalp conditions after starting tirzepatide. The proposed mechanism: tirzepatide's dual GLP-1/GIP agonism produces strong improvements in insulin sensitivity, which reduces inflammation at the follicle level.
The TriNetX cohort study also found that alopecia areata (autoimmune hair loss) was actually lower in GLP-1 users than matched controls. Patients with insulin-resistant conditions like PCOS may see improved hair health from the metabolic benefits of GLP-1 therapy.
How to Choose: Hair Loss as One Factor Among Many
Consider semaglutide if:
- You have pre-existing hair thinning or family history of AGA
- You prefer more gradual weight loss (~15%)
- Your insurance covers Wegovy specifically
- You're comfortable with slightly lower efficacy for potentially less hair impact
Consider tirzepatide if:
- Maximizing weight loss is your primary goal
- You have insulin resistance (potential hair benefit)
- You're willing to implement aggressive nutritional support
- Your prescriber recommends it based on metabolic profile
The bottom line
Neither drug is clearly "safer" for hair. The difference in hair loss rates is primarily driven by the difference in weight loss magnitude. If you implement the prevention protocol from our prevention guide — baseline labs, aggressive protein intake, targeted supplementation, and potentially prophylactic minoxidil — you can meaningfully reduce your risk on either medication.
Get Personalized Guidance on GLP-1 and Hair Health
A provider can help you choose the right medication and build a hair-protection plan tailored to your risk profile.
Start Your Consultation — Care Bare RxFor current pricing across GLP-1 platforms, visit GLP-1PriceList.com. For telehealth platform reviews, see HealthyWeightMeds.com.